Skip to main content
PMC home page
Nature Communications logoLink to Nature Communications
. 2021 Oct 29;12:6233. doi: 10.1038/s41467-021-26551-x

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Wei-Yu Lin 1, Sarah E Fordham 1, Eric Hungate 2, Nicola J Sunter 1, Claire Elstob 1, Yaobo Xu 1, Catherine Park 1, Anne Quante 3,4, Konstantin Strauch 3,4, Christian Gieger 4, Andrew Skol 2, Thahira Rahman 1, Lara Sucheston-Campbell 5, Junke Wang 5, Theresa Hahn 6, Alyssa I Clay-Gilmour 7, Gail L Jones 8, Helen J Marr 8, Graham H Jackson 8, Tobias Menne 8, Mathew Collin 8, Adam Ivey 9, Robert K Hills 10, Alan K Burnett 11, Nigel H Russell 12, Jude Fitzgibbon 13, Richard A Larson 2, Michelle M Le Beau 2, Wendy Stock 2, Olaf Heidenreich 1, Abrar Alharbi 1, David J Allsup 14, Richard S Houlston 15, Jean Norden 16, Anne M Dickinson 16, Elisabeth Douglas 16, Clare Lendrem 16, Ann K Daly 16, Louise Palm 17, Kim Piechocki 17, Sally Jeffries 17, Martin Bornhäuser 18,19,20, Christoph Röllig 20, Heidi Altmann 20, Leo Ruhnke 20, Desiree Kunadt 20, Lisa Wagenführ 20, Heather J Cordell 21, Rebecca Darlay 21, Mette K Andersen 22, Maria C Fontana 23,24, Giovanni Martinelli 24, Giovanni Marconi 24, Miguel A Sanz 25,26, José Cervera 25,26, Inés Gómez-Seguí 25,26, Thomas Cluzeau 27, Chimène Moreilhon 27, Sophie Raynaud 27, Heinz Sill 28, Maria Teresa Voso 29, Francesco Lo-Coco 29, Hervé Dombret 30, Meyling Cheok 31, Claude Preudhomme 31, Rosemary E Gale 32, David Linch 32, Julia Gaal-Wesinger 33, Andras Masszi 34, Daniel Nowak 35, Wolf-Karsten Hofmann 35, Amanda Gilkes 36, Kimmo Porkka 37, Jelena D Milosevic Feenstra 38, Robert Kralovics 38, David Grimwade 9, Manja Meggendorfer 39, Torsten Haferlach 39, Szilvia Krizsán 40, Csaba Bödör 40, Friedrich Stölzel 20,✉, Kenan Onel 41,✉, James M Allan 1,✉
PMCID: PMC8556284  PMID: 34716350

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 10488 controls. We identify a genome-wide significant risk locus for AML at 11q13.2 (rs4930561; P = 2.15 × 10−8; KMT5B). We also identify a genome-wide significant risk locus for the cytogenetically normal AML sub-group (N = 1287) at 6p21.32 (rs3916765; P = 1.51 × 10−10; HLA). Our results inform on AML etiology and identify putative functional genes operating in histone methylation (KMT5B) and immune function (HLA).

Subject terms: Acute myeloid leukaemia, Cancer genomics, Risk factors

Genome wide association studies in cancer are used to understand the heritable genetic contribution to disease risk. Here, the authors perform a genome wide association study in European patients with acute myeloid leukemia and identify loci associated with risk of developing the disease.

Introduction

Acute myeloid leukemia (AML) is the most common acute leukemia in adults of European ancestry1 comprising distinct sub-groups characterized by unique somatic genetic alterations, etiologies, and outcomes2. Rare germline variants in transcription factors and other genes regulating hematopoietic cell differentiation and proliferation are highly penetrant for AML3, with some causative for debilitating human syndromes that include AML as a component, while others cause familial AML with high penetrance. Although such variants demonstrate a role for genetics in AML susceptibility, they are rare and do not make a major contribution to population disease burden4. A modest increased risk of myeloid malignancy for first-degree relatives of non-familial AML patients further supports a role for genetics in disease susceptibility5, which for the majority of cases is likely determined by co-inheritance of common low penetrance variants consistent with the multigenic model for complex human diseases6,7.

Outside of highly penetrant syndromic or familial disease, genetic susceptibility to AML remains largely unexplained. To identify AML risk loci we conducted three genome-wide association studies with participants of European ancestry, with replication in a fourth study. Here we report the identification of risk loci for AML, including pan-AML irrespective of disease sub-type and for cytogenetically normal AML. These data inform on disease etiology and demonstrate the existence of common, low-penetrance susceptibility alleles for AML with heterogeneity in risk across sub-types.

Results

Discovery meta-analysis of AML genome-wide association studies (GWAS)

We conducted three independent genome-wide association studies with AML cases and controls of European ancestry (GWAS 1-3). Following implementation of rigorous quality metrics to each GWAS (Methods, Supplementary Fig. 1), genotype data were available on 3041 AML cases and 6760 controls of European ancestry (Supplementary Figs. 2–5, Supplementary Table 1). To improve genomic resolution, imputation using the Haplotype Reference Consortium panel (http://www.haplotype-reference-consortium.org/)8 was used to derive estimated genotypes for >7 million single nucleotide polymorphisms (SNPs) for each study. We combined the association test statistic for 6694056 autosomal SNPs common to all three GWAS after exclusion of those with an INFO (imputation quality) score of <0.6 and a minor allele frequency (MAF) of <0.01, and conducted a meta-analysis under a fixed-effect model for variants associating with AML. Given the genetic and biological heterogeneity of AML, sub-type specific odds ratios (ORs) were also calculated for the largest AML sub-group, cytogenetically normal AML (N = 822), using data for 6532175 SNPs common to all three studies. Quantile-quantile plots of observed versus expected P values (minor allele frequency (MAF) >0.01) for all AML cases and cytogenetically normal AML cases showed minimal inflation of test statistics across all three GWAS after adjustment for nominally significant principal components in each GWAS (λGC = 1.021, 1.025, and 1.055 for all AML in GWAS1, GWAS2, and GWAS3, respectively; λGC = 1.006, 1.011, and 1.025 for cytogenetically normal in GWAS1, GWAS2, and GWAS3, respectively) (Supplementary Figs. 6–7), minimizing the possibility of hidden population stratification and cryptic relatedness. Pooling data from three GWAS identified associations for cytogenetically normal AML at 6p21.32 (rs3997854, HLA-DQA2) and 4q22.3 (rs75391980) that surpassed genome-wide significance (P ≤ 5 × 10−8), and additional suggestive associations (P < 10−6) at 2q36.1 (rs4674579), 3q (rs2621279), 5q35.1 (rs13183143), 11q13.2 (rs11481), and 20p12.3 (rs6077414) for all AML and at 9p21.1 (rs10969985) and 13q21.31 (rs143280565) for cytogenetically normal AML (Supplementary Fig. 8, Supplementary Table 2).

Validation GWAS and meta-analysis

To replicate the associations at the loci identified in the discovery GWAS meta-analysis we conducted a fourth genome-wide association study of European cases and controls (GWAS 4). Following the application of SNP and sample quality control metrics (Supplementary Figs. 9 and 10), data on >7.6 million SNPs from 977 AML cases and 3728 controls of European ancestry were available for analysis, which included 465 cytogenetically normal AML cases (Supplementary Table 1). Quantile–quantile plots of observed versus expected P values (MAF > 0.01) showed minimal inflation of test statistics (λGC = 1.012 for all AML cases and λGC = 1.001 for cytogenetically normal AML) (Supplementary Fig. 11). Analysis of data from GWAS 4 validated (P < 0.05) two of the associations identified in the discovery GWAS meta-analysis, with consistent direction and magnitude of effect sizes across all four studies, including 11q13.2 (rs4930561, KMT5B; P = 2.15 × 10−8) for all AML irrespective of sub-type (N = 4018) and 6p21.32 (rs3916765, HLA-DQA2; P = 1.51 × 10−10) for cytogenetically normal AML (N = 1287). Meta-analysis of SNPs common to all four GWAS (N = 6661818 and N = 6496414 for all AML and cytogenetically normal AML, respectively) also revealed additional borderline significant susceptibility loci at 1p31.1 (rs10789158, CACHD1, P = 2.25 × 10−7) for all AML and at 7q33 (rs17773014, AKR1B1, P = 4.09 × 10−7) for cytogenetically normal AML, both with consistent direction and magnitude of effect across all four studies (Figs. 1 and 2). In order to test for any potential effects of residual population substructure we re-examined the top signals using only cases and controls of UK origin in GWAS1, GWAS2, and GWAS4, and using only cases and controls of German origin in GWAS3 (Supplementary Fig. 12). The direction and magnitude of the associations in these sub-group analyses (Supplementary Fig. 13) are very similar to the analyses including all cases and controls (Fig. 2). As such, we report genome-wide significant susceptibility loci for all AML and cytogenetically normal AML at 11q13.2 (rs4930561) and 6p21.32 (rs3916765), respectively, and borderline significant susceptibility loci for all AML and cytogenetically normal AML at 1p31.1 (rs10789158) and 7q33 (rs17773014).

Fig. 1. Manhattan plots from acute myeloid leukemia meta-analysis of 4 genome-wide association studies.

Fig. 1

Open in a new tab

For each GWAS, association tests were performed for all AML cases and cytogenetically normal AML assuming an additive genetic model, with nominally significant principal components included in the analysis as covariates. Association summary statistics were combined for variants common to all four GWAS, in fixed effects models using PLINK. Manhattan plots show negative log10 (fixed effects meta P values, Y axis) for all AML (a) and cytogenetically normal AML (b) over 22 autosomal chromosomes. Risk loci are annotated with chromosome position and local gene. All statistical tests were two-sided and no adjustments were made for multiple comparisons. The horizontal red line denotes the threshold for statistical significance in a genome-wide association study (P < 5.0 × 10−8).

Fig. 2. Forest plots for 4 new loci associated with acute myeloid leukemia.

Fig. 2

Open in a new tab

Study cohorts, sample sizes (case and controls (con)), imputation (info) score, effect allele, effect allele frequencies (EAF), and estimated odds ratios (OR) for rs4930561 (a), rs3916765 (b), rs10789158 (c), and rs17773014 (d). The vertical line corresponds to the null hypothesis (OR = 1). The horizontal lines and square brackets indicate 95% confidence intervals (95% CI). Areas of the boxes are proportional to the weight of the study. Diamonds represent combined estimates for fixed‐effect and random‐effect analysis. Cochran’s Q statistic was used to test for heterogeneity such that PHET > 0.05 indicates the presence of non-significant heterogeneity. The heterogeneity index, I2 (0–100) was also measured which quantifies the proportion of the total variation due to heterogeneity. All statistical tests were two-sided and no adjustments were made for multiple comparisons.

AML risk variants at 11q13.2, 6p21.32, 1p31, and 7q33 have Bayesian false-discovery probabilities (BFDP)9 of 7, <1, 3, and 5%, respectively. There was no evidence of significant heterogeneity (P < 0.05) for association with AML for any of the risk variants across the 4 GWAS studies (Fig. 2). Analysis conditioning on the top variant at each susceptibility locus did not identify any evidence of additional associations (P < 10−4) within 500 kb of the lead variant (Supplementary Figs. 14–17).

There was no significant heterogeneity in AML risk for any of the four variants when cases and controls were stratified by age (<55 years; ≥55 years) (Supplementary Table 3). Likewise, there was no significant heterogeneity in AML risk for rs4930561 (11q13.2), rs10789158 (1p31.3), or rs17773014 (7q33) when cases and controls were stratified by sex, although there was significant heterogeneity for rs3916765 (6p21.32) with greater penetrance for cytogenetically normal AML in females (OR 2.11, 95% CI 1.63–2.73) compared to males (OR 1.45, 95% CI 1.16–1.80; I2 = 78.47, PQ = 0.03) (Supplementary Table 4).

The relationship between AML risk variants and survival was evaluated in 767 AML patients (excluding acute promyelocytic leukemia) from the UK, Germany, and Hungary. However, none of the 4 AML susceptibility variants identified here were significantly associated with either relapse-free or overall survival in univariate analysis that included all AML patients (N = 767) or those with cytogenetically normal AML (N = 369) (Supplementary Figs. 18–21).

A previously reported susceptibility variant for AML in the BICRA gene (rs75797233)10 was not significantly associated with AML risk in our study (GWAS meta-analysis odds ratio (OR) 1.06, 95% CI 0.87–1.29). However, this variant was imputed to sufficient quality (INFO > 0.6) in only three GWAS studies and statistical power to detect an association with AML for this relatively uncommon variant (MAF 0.02) is compromised.

Inference of risk loci and biological function

We identified a genome-wide significant association for rs4930561 with risk of AML irrespective of sub-type (OR 1.17, 95% CI 1.11–1.24; P = 2.15 × 10−8) which maps to the KMT5B gene on 11q13.2 (Fig. 3a). To identify putative risk loci we interrogated data from a meta-analysis of 31624 blood samples collated by the eQTLGen consortium11 for evidence of cis-regulated genes. Forty seven genes annotated to within 500 Kb of the association signal and the sentinel variant is a significant eQTL for 12 of these, including MRPL21 (Benjamini–Hochberg corrected P-value [PBH] = 7.5 × 10−29), RP5-901A4.1 (PBH = 4.1 × 10−24), ALDH3B1 (PBH = 4.48 × 10−18), IGHMBP2 (PBH = 2.85 × 10−16), RP11-802E16.3 (PBH = 6.76 × 10−15), and CHKA (PBH = 1.73 × 10−14), DOC2GP (PBH = 1.32 × 10−12), TCIRG1 (PBH = 7.83 × 10−5), NDUFS8 (PBH = 1.69 × 10−4), UNC93B1 (PBH = 1.09 × 10−3), PP1CA (PBH = 0.01), and RP11-554A11.9 (PBH = 0.01). rs4930561 is not, however, an eQTL for KMT5B (PBH = 0.99) (Supplementary Table 5).

Fig. 3. Regional association and linkage disequilibrium plots for 4 new loci associated with acute myeloid leukemia.

Fig. 3

Open in a new tab

For each GWAS, association tests were performed for all AML cases and cytogenetically normal AML assuming an additive genetic model, with nominally significant principal components included in the analysis as covariates. Association summary statistics were combined for variants common to all four GWAS, in fixed effects models using PLINK. Negative log10-transformed P values (left Y axis) from the meta-analysis of four GWAS are shown for SNPs at 11q13 (a) and 1p31.1 (c) for all AML irrespective of sub-type, and at 6p21.32 (b) and 7q33 (d) for cytogenetically normal AML. All statistical tests were two-sided and no adjustments were made for multiple comparisons. The lead SNP at each location is indicated by a purple diamond and the blue line shows recombination rate (right Y axis). All plotted SNPs were either directly genotyped or had an imputation score of >0.6 in all four GWAS datasets. Included are functional annotation tracks from ENCODE showing regulatory activity in H1 human embryonic stem cells (H1hesc) and K562 myeloid leukemia cells. TSS transcription start site, PF promoter flank, E enhancer, WE weak enhancer, CTCF CCCTC-binding factor site, T transcribed.

We identified strong statistical evidence for an association with cytogenetically normal AML for rs3916765 (OR 1.72, 95% CI 1.46–2.03; P = 1.51 × 10−10), which maps to the HLA locus on 6p21.32, intergenic to HLA-DQB1 and HLA-DQA2 within the major histocompatibility (MHC) class II region (Fig. 3b). To further explore the association between the HLA locus and risk of cytogenetically normal AML we imputed classical HLA alleles using 5225 Europeans from the Type I Diabetes Genetics Consortium12 as a reference panel (Methods). HLA-DQB1*03:02 (r2 = 0.56 with rs3916765) was significantly under-represented in AML cases compared to controls in meta-analysis (OR 0.63, 95% CI 0.51–0.72, P = 8.9 × 10−8), identifying this as the most likely classical HLA allele underpinning the association with AML at the 6p21.32 locus (Supplementary Fig. 22). Likewise, HLA-DQA1*03:01 (r2 = 0.53 with rs3916765) was also significantly under-represented in cases compared to controls (OR 0.77, 95% CI 0.68–0.87, P = 4.91 × 10−5) (Supplementary Fig. 22). However, analysis conditioning on HLA-DQB1*03:02 rendered the association for the HLA-DQA1*03:01 allele non-significant (OR 0.98, 95% CI 0.82–1.16, P = 0.79), consistent with linkage disequilibrium between these two alleles (r 2 = 0.50).

Given the identification of a major AML risk allele at the HLA locus on chromosome 6p21.32 and that cancer cells acquire somatic mutations that can function as neo-antigens for immune recognition we performed a case–control analysis stratified by mutation status for NPM1 and FLT3, two genes commonly mutated and clinically significant in cytogenetically normal AML2. Specifically, data on NPM1 and FLT3 somatic mutation status were available for 653 and 865 AML cases, respectively. There was no significant heterogeneity in AML risk when cases and controls were stratified by either NPM1 or FLT3 mutation status, although there was a trend towards higher risk for NPM1-mutated AML (OR 1.96, 95% CI 1.29–2.98; P = 1.7 × 10−3) and FLT3-mutated AML (OR 1.52, 95% CI 1.07–2.16; P = 0.02) compared to NPM1-wildtype AML (OR 1.28, 95% CI 0.97 –1.68; P = 0.08) or FLT3-wildtpe AML (OR 1.26, 95% CI 1.01–1.58; P = 0.04) (Supplementary Table 6).

We also identified a borderline significant association for rs10789158 with AML irrespective of sub-type (OR 1.22, 95% CI 1.13–1.31; P = 2.25 × 10−7) which maps to a block of linkage disequilibrium upstream of the CACHD1 gene on chromosome 1p31.3 (Fig. 3c). Of the 11 genes annotated to within 500 Kb of the association signal, the sentinel SNP (rs10789158) is eQTL for RAVER2 (PBH = 1.26 × 10−2) and AK4 (PBH = 1.26 × 10−2) where the AML risk variant is associated with higher expression of AK4 and lower expression of RAVER2 (Supplementary Table 7).

We also identified a borderline statistically significant association with cytogenetically normal AML for rs17773014 (OR 1.26, 95% CI 1.15–1.37; P = 4.09 × 10−7), which maps close to the AKR1B1 gene on chromosome 7q33 (Fig. 3d). Nine genes were annotated to within 500 Kb of the association signal and the sentinel SNP (rs17773014) is a significant eQTL for AKR1B1 in whole blood with the AML risk allele associated with higher transcript levels (PBH = 5.32 × 10−23) (Supplementary Table 8). We cannot exclude an association with related superfamily member AKR1B10, which maps close to AKR1B1 on chromosome 7q33 but which was not annotated in the eQTLGen consortium dataset.

Discussion

By conducting a meta-analysis of three large genome-wide studies with validation in a fourth study, we identify four susceptibility loci for AML, demonstrating the existence of common, low-penetrance susceptibility alleles for this genetically complex disease. Specifically, our data identify a major susceptibility locus for AML at the 11q13.2 KMT5B gene. KMT5B (SUV420H1) encodes a lysine methyltransferase that is frequently mutated in human cancers, with gene amplifications being particularly common13–15. KMT5B is implicated in AML pathogenesis where mutation has been associated with transformation from precursor myelodysplastic syndrome to AML16. Mutations in other lysine methyltransferases such as KMT2A (MLL1) occur with high frequency in AML17. Although KMT5B is a strong candidate for an AML susceptibility gene a priori we cannot exclude mechanisms involving other local genes. For example, the AML risk variant at the 11q13.2 susceptibility locus is significantly associated with lower expression of CHKA, which encodes a protein involved in phosphatidylcholine biosynthesis. CHKA is significantly upregulated in mouse haematopoietic stem cells and human leukemia cell lines upon restoration of TET2 function18, a tumor suppressor which blocks aberrant self-renewal and which is frequently mutated in AML resulting in loss of function19.

We also report a putative pan-AML susceptibility locus at 1p31.3 that is cis-eQTL for RAVER2 and AK4. RAVER2 encodes a ribonucleoprotein involved in RNA splicing where expression associates with transformation from myelodysplastic syndrome to AML20. In both human and mouse hematopoietic stem cells RAVER2 is identified as a target gene for miR-9921, which regulates normal and malignant hematopoietic stem cell self-renewal21,22 and expression is significantly associated with prognosis in AML22. AK4 belongs to the adenylate kinase (AK) family of proteins that catalyze the phosphorylation of nucleotide monophosphate precursors to their di- and triphosphate forms. AK4 is localized to the mitochondria and is a target gene for hypoxia-inducible factor 1 alpha (HIF-1α)23, an established tumor suppressor in human and murine AML24,25.

We also identify a major susceptibility locus for cytogenetically normal AML at the 6q21.32 HLA gene. This region carries susceptibility alleles for numerous human cancers including hematological malignancies such as chronic lymphocytic leukemia26,27 and Hodgkin lymphoma28, where risk is mediated via differential antigenic presentation/T-cell receptor recognition or altered risk of oncogenic infection. Somatic dysregulation of antigenic presentation through altered gene expression, loss of heterozygosity or genomic deletion is a common feature of many human solid cancers leading to failed immune surveillance29–31. Somatic loss of HLA alleles is rare in AML at disease presentation although it has been reported as a mechanism of immune escape after bone marrow transplant leading to relapse32–35. Our data identify the HLA-DQB1*03:02 and HLA-DQA1*03:01 alleles as significantly under-represented in cytogenetically normal AML cases compared to controls. Cytogenetically normal AML is characterized by somatic mutation in genes such as NPM1 and FLT32 which can function as neo-antigens36–40. For example, NPM1 mutation is reported in up to 60% of cytogenetically normal AML41,42 where mutation leads to aberrant cytoplasmic expression that is postulated to lead to more efficient HLA presentation43. Our data suggest that rs3916765 affects AML risk by modulating immune recognition of mutated cells, although further work is required to determine which leukemia-specific neo-antigens are involved. The DQB1*03:02-DQA1*03:01 haplotype is associated with increased risk of autoimmune diseases including celiac disease44 and type 1 diabetes45,46. Reports of concomitant celiac disease and AML are very rare47 consistent with the DQB1*03:02-DQA1*03:01 haplotype having pleiotropic and opposing effects on risk of these two diseases. Taken together, these data implicate dysregulated immune function as a risk modifier for cytogenetically normal AML.

Our data suggest that differential expression of cis-regulated AKR1B1 (or related superfamily member AKR1B10) at the 7q33 locus modulates risk of cytogenetically normal AML. AKR1B1 and AKR1B10 encode members of the aldo-ketoreductase superfamily which catalyze the reduction of numerous aldehydes, including the aldehyde form of glucose to generate fructose via the polyol pathway48. Altered glucose metabolism is a hallmark of cancer, where malignant cells switch energy production from mitochondrial oxidative phosphorylation to glycolysis49. In AML, a switch to glycolytic metabolism is associated with disease progression and poor outcome50. Unlike normal monocytes, AML cells can also utilize fructose as an alternative substrate for glycolysis with expression of the GLUT5 fructose transporter as a major regulator of fructose metabolism in leukemic blast cells51,52, and where high expression is associated with increased proliferation, clonogenicity, migration, and invasion of AML cells51. Interrogation of three independent datasets identified a consistent association between elevated AKR1B1 transcript levels and shorter overall survival in AML53 and serum fructose levels are prognostic in AML51, further implicating this pathway in AML disease progression.

In summary, our study identifies common susceptibility alleles at four genomic locations that modify AML risk, with evidence of sub-type specific risk loci reflecting the existence of multiple etiological pathways to disease development. Further work is required to decipher the functional basis of these risk loci although our data builds on existing evidence demonstrating a role for aberrant histone modification and altered fructose metabolism in AML pathogenesis16,17,51,52. Furthermore, the identification of a major AML risk variant at the HLA locus on chromosome 6 implicates altered immune function as etiologically important in AML. Our data supports existing evidence of genetic and biological heterogeneity in AML2 and confirm the need for large collaborative studies to improve statistical power and aid the discovery of sub-type specific genetic risk loci.

Methods

Study participants

GWAS1 comprised 1119 AML cases of European ancestry from UK Medical Research Council/National Cancer Research Institute AML clinical trials (N = 529)54,55, the Eurobank transplant study (N = 70)56, the Leukaemia and Lymphoma Research adult acute Leukaemia population-based case control epidemiology study (N = 222)57,58, and the institutional hematology biobanks of Newcastle University (N = 48) and University of Chicago (N = 250). Cases were genotyped on the Illumina Omni Express/Omni Express Exome BeadChips. For controls, we used publicly available Illumina Hap550K BeadChip data on 2671 individuals from the British 1958 Birth Cohort59.

GWAS2 comprised 931 AML cases of European ancestry from the Central England Haemato-Oncology and Oncology Research Bank (N = 120) and King’s College London Medical School (N = 144) with cases recruited from local treatment centers and UK clinical trials. AML cases were also obtained from the Study Alliance Leukemia biobank at Dresden University (N = 208)60,61, the CALGB 9710 APL clinical trial (N = 101)62, the Newcastle University Haematology Biobank (N = 248), and the Munich Leukemia Laboratory (N = 53) which provides a nationwide diagnostic service in Germany. AML cases were also obtained from treatment centers at the Medical University of Graz (N = 32), University Hospital Rigshospitalet Copenhagen (N = 13), and the Universita Cattolica Sacro Cuore Rome (N = 12). All cases were genotyped on the Illumina Omni Express Exome BeadChip. For controls, we used publicly available Illumina Hap1.2M-Duo data on 2477 individuals from the UK Blood Service Control Group, part of the Wellcome Trust Case Control Consortium 2 controls63.

GWAS3 comprised 991 AML cases of European ancestry from treatment centers at the Department of Hematology and Oncology of the Medical Faculty Mannheim, University of Heidelberg, Germany (N = 82)64, the Centre Hospitalier Universitaire Nice, France (N = 42)65, and the University of London UK (GSE20672) (N = 40). AML cases were also obtained from the Austrian Academy of Sciences (N = 223)66, the Acute Leukaemia French Association Clinical Trials at the University of Lille, France (N = 278)67,68, the Biobank La Fe at the Hospital Universitari i Politècnic La Fe, Spain (N = 15)69, the German-Austria AML Study Group the German-Austrian AML Study Group (GSE32462, N = 18970; GSE34542, N = 3371; GSE46745, N = 33; GSE46951, N = 5172), and the Cooperative Health Research in the region of Augsburg (KORA) study (N = 5)73. For controls, we used data from 1612 individuals recruited to KORA study73. All genotyping data for cases and controls were generated on the Affymetrix SNP6.0 Array.

GWAS4 (replication) comprised 977 AML cases of European ancestry from the Central England Haemato-Oncology and Oncology Research Bank (N = 515), treatment centers at the Hematology Division at Semmelweis University, Budapest (N = 202)74 and the UK Biobank (N = 260), a large population-based study conducted in the United Kingdom. For controls, we used 3728 individuals from the UK Biobank. Cases and controls were genotyped on the Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank Axiom array with an equal proportion of cases and controls genotyped on each array.

Collection of patient samples and associated clinico-pathological information was undertaken with written informed consent. All studies were conducted in accordance with the Declaration of Helsinki and received local institutional review board or national research ethics approval (Supplementary Table 9). Specifically, this research has been conducted using the UK Biobank Resource (Application #16583, James Allan). MRC/NCRI AML 11 trial, AML 12 trial and the UK Leukaemia Research Fund (LLR) population-based case–control study of adult acute leukemia received multicenter research ethics committee approval54,55,75. Research ethics committee approval was given to the Newcastle Haematology Biobank (07/H0906/109 + 5) and the AML genome-wide association study in the UK (06/q1108/92, BH136664 (7078)). AML cases and controls for Samples from the Hungarian AML patients were obtained during the standard diagnostic workup at the Hematology Divisions of the 1st and 3rd Department of Internal Medicine, Semmelweis University, Budapest, following ethical approval from the Local Ethical Committee (REF TUKEB-1552012) and the Hungarian Medical Research Council (REF 45371-2/2016/EKU). Saliva and fibroblast samples from Austrian AML patients were collected at the Division of Hematology, Medical University of Graz, Graz, Austria76. The diagnosis of AML was made in accordance with World Health Organisation guidelines.

Genotyping and genome-wide quality-control procedures

Genotype calling was performed using Illumina GenomeStudio software or Affymetrix Genotyping Console software v4.2.0.26. Data handling and analysis was performed using R v3.5.1, PLINK v1.9b4.4, and SNPTEST v2.5.2. Rigorous SNP and sample quality control metrics were applied to all four GWAS (Supplementary Fig. 1). Specifically, we excluded SNPs with extreme departure from Hardy–Weinberg equilibrium (HWE; P < 10−3 in either cases or controls) and with a low call rate (<95%). We also excluded SNPs that showed significant differences (P < 10−3) between genotype batches and with significant differences (P < 0.05) in missingness between cases and controls. Individual samples with a call rate of <95% or with extreme heterozygosity rates (±3 standard deviation from the mean) were also excluded from each GWAS. Individuals were removed such that there were no two individuals with estimated relatedness pihat >0.1875, both within and across GWAS. The individual with the higher call rate was retained unless relatedness was identified between a case and a control, where the case was preferentially retained. Ancestry was assessed using principal component analysis and super-populations from the 1000 genomes project as a reference, with individuals of non-European ancestry excluded based on the first two principal components. In order to minimize any impact of population stratification among the European population we excluded outlying cases and controls identified using principal components 1 and 2 for each GWAS (Supplementary Figs. 1, 3, 4, 5, and 10).

Imputation, genome-wide association testing, and meta-analysis

Genome-wide imputation for each GWAS was performed using the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html#!) and the Haplotype Reference Consortium reference haplotype panel (http://www.haplotype-reference-consortium.org/) following pre-phasing using ShapeIT (v2.r790)77. All variants with an imputation info score <0.6 or a minor allele frequency of <0.01 were excluded from subsequent analysis.

For each GWAS, association tests were performed for all cases and cytogenetically normal AML assuming an additive genetic model, with nominally significant principal components included in the analysis as covariates. Association summary statistics were combined for variants common to GWAS 1, GWAS 2, and GWAS 3, and then for variants common to all four GWAS, in fixed effects models using PLINK v1.9b4.4. Cochran’s Q statistic was used to test for heterogeneity and the I2 statistic was used to quantify variation due to heterogeneity.

The Bayesian false discovery probability was calculated using a prior probability of association of 0.0001 and a plausible OR of 1.39.

Case–control analyses were also performed stratified by sex and age in all 4 GWAS. For age, cases and controls were stratified into those <55 years and ≥55 years. GWAS 1 was not included in the meta-analysis for the ≥55 age group because the controls were recruited to the 1958 Birth Cohort and were all genotyped at the age of 45 years. Case–control analyses were performed stratified by NPM1 and FLT3 mutation status (mutation-positive and mutation-negative) in GWAS 2 and GWAS 4. Data on NPM1 and FLT3 somatic mutation status was available for 653 and 865 AML cases, respectively, including 411 and 528 cases of cytogenetically normal AML, respectively. PCR mutation analysis was performed as part of routine diagnostics for NPM1 exon 12 and FLT3 exons 14–15 (Supplementary Table 10)78,79.

Technical validation of AML susceptibility variants

All four AML risk variants reported here were either directly genotyped or imputed to high quality. Specifically, rs4930561 was directly genotyped in GWAS 1 and GWAS 2 and imputed in GWAS 3 and GWAS 4 (info score 0.974–0.988); rs3916765 was genotyped in GWAS 4 and imputed in GWAS 1, GWAS 2, and GWAS 3 (info score 0.901–0.995); rs10789158 was imputed in all 4 GWAS studies (info score 0.946–0.9775); and rs17773014 was directly genotyped in GWAS 3 and GWAS 4 and imputed in GWAS 1 and GWAS 2 (info score 0.985–0.993). Fidelity of array genotyping and imputed dosages was confirmed using Sanger sequencing in a subset of AML samples (including samples genotyped on both Illumina and Affymetrix platforms) for each sentinel variant with perfect or very high concordance for all four variants (Supplementary Figs. 23–26).

The majority of AML cases were genotyped using DNA extracted from cell/tissue samples (blood and bone marrow) taken during AML remission. A minority of AML cases were genotyped using DNA extracted from tissue samples that include leukemic AML cells. As such, we employed a stringent HWE cut-off (Supplementary Fig. 1) in order to eliminate SNPs potentially affected by somatic copy number alterations. Furthermore, we also used Nexus Copy Number v10 (BioDiscovery, California) to interrogate B allele frequency and Log R ratio values at loci associated with AML following genotyping of DNA extracted from leukemic AML cells. For rs4930561 (chromosome 11q13.2) we interrogated data from 352 AML cases using samples with high somatic cell content and found one case with a large deletion capturing the KMT5B locus. We also identified 12 cases with evidence of trisomy 11 or large gains affecting chromosome 11, consistent with reports of trisomy 11 in approximately 1% of AML cases80. For rs10789158 (chromosome 1p31.3) we identified 1 case with evidence of copy number gain. The susceptibility locus at chromosome 1 does not fall within a region reported to be recurrently somatically deleted or amplified in AML. The association signals at 6p21.32 (rs3916765) and 7q33 (rs17773014) were specific to cytogenetically normal AML and evidence of somatic copy number alterations were visible in 0 and 3 cases, respectively (based on Nexus Copy Number analysis of 127 cytogenetically normal AML cases). Specifically, there were three cases with evidence of deletions affecting the chromosome 7 risk locus that were not visible cytogenetically. Furthermore, there was no evidence of copy neutral loss of heterozygosity (>2 Mb) at any of the four AML susceptibility loci reported here. Taken together, these data limit the possibility of differential genotyping in cases and controls due to somatically acquired allelic imbalance.

HLA imputation, expression quantitative trait loci (eQTL) analysis, and functional annotation

Imputation of classical HLA alleles was performed using the SNP2HLA v1.0.3 tool using 5225 Europeans from the Type I Diabetes Genetics Consortium as a reference panel12. To examine the relationship between SNP genotype and gene expression and identify cis expression quantitative trait loci (eQTLs) we made use of data from the eQTLGen Consortium (http://www.eqtlgen.org/cis-eqtls.html) for whole blood. Benjamini–Hochberg (BH)-adjusted P values were estimated for each gene annotated to within 1 Mb of the sentinel SNP at each AML association signal. Regions with AML susceptibility variants were annotated for putative functional motifs using data from the ENCODE project81.

Relationship between SNP genotype and patient survival

The relationship between AML risk variants and survival was evaluated in a total of 767 AML patients (excluding acute promyelocytic leukemia) from the UK54,55, Germany60,61, and Hungary74. Briefly, patients were treated with conventional intensive AML therapy including ara-C, daunorubicin, and best supportive care. A subset of high-risk patients in the German cohort were treated with stem cell transplantation60. Overall survival was defined as the time from diagnosis to the date of last follow-up or death from any cause. Data on relapse-free survival was available on 358 AML patients, which was defined as the time from date of first remission to the date of last follow-up in remission or date of AML relapse. Cox regression analysis was used to estimate allele-specific hazard ratios and 95% confidence intervals for each study in analyses that included all AML cases (N = 767) and cytogenetically normal AML (N = 358).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

Supplementary Information (8.4MB, pdf)
Peer Review File (1MB, pdf)
Reporting summary (220.2KB, pdf)

Acknowledgements

This work was funded by Blood Cancer UK (to JMA; #06002 and #13044). The Hungarian AML study was funded by the Hungarian National Research, Development and Innovation Office (NKFIH) (NVKP_16-1-2016-0004), a Momentum grant (LP- 95021) from the Hungarian Academy of Sciences and EU’s Horizon 2020 research and innovation program under grant agreement No. 739593. The KORA study was initiated and financed by the Helmholtz Zentrum München—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. The recruitment of cases via the Catholic University of Rome was funded by Progetto AIRC 5permille Mynerva. DN is an endowed Professor of the Deutsche Jose Carreras Leukaemie Stiftung (DJCLS H 03/01) and is funded by the H.W. & J. Hector fund, Baden Wuerttemberg and the Dr. Rolf M. Schwiete Fund, Mannheim. MM is employed by the Munich Leukemia Laboratory and TH is part owner of the Munich Leukemia Laboratory. We are grateful to the Newcastle University Biobank (https://www.ncl.ac.uk/biobanks/) for providing samples.

Author contributions

W.-Y.L. collated data, conducted data analysis, and drafted the manuscript. S.E.F., N.S., C.E., C.Pa., A.Q., K.S., C.G., L.S.-C., J.W., T.Hah., A.I.C.-G., G.L.J., H.J.M., G.H.J., T.M., M.Co., A.I., R.K.H., A.K.B., N.H.R., J.F., R.A.L., M.M.L.B., W.S., O.H., A.A., D.J.A., R.S.H., J.N., A.M.D., E.D., C.L., A.K.D., L.P., K.Pi., S.J., M.B., C.R., H.A., L.R., D.K., L.W., H.J.C., R.D., M.K.A., M.C.F., G.Mart., G.Marc., M.A.S., J.C., I.G.-S., T.C., C.M., S.R., H.S., M.T.V., F.L.-C., H.D., M.Ch., C.Pr., R.E.G., D.L., J.G.-W., A.M., D.N., W.-K.H., A.G., K.Po., J.D.M.F., R.K., D.G., M.M., T.Haf., S.K., and C.B. collated data and/or advised on data analysis. E.H., Y.X., T.R., and A.S. contributed to preliminary data collation and analysis. F.S. conceived of the project and collated data. K.O. conceived of the project, collated data, and supervised preliminary data analysis. J.M.A. conceived of the project, collated data, analyzed data, directed the research, obtained funding, and drafted the manuscript. All authors approved the final version of the manuscript, with the exception of E.D. (deceased), F.L.-C. (deceased) and D.G. (deceased).

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

Genome-wide association summary statistics (Lin_AML_metaassoc.txt) are available for download from 10.25405/data.ncl.16558116.v1. AML case and control genotyping data from the UK Biobank can be obtained via application through https://www.ukbiobank.ac.uk/. Genotyping data on 2699 individuals recruited to the 1958 British Birth Cohort (Hap1.2M-Duo Custom array data) and 2501 individuals from the UK Blood Service are available from the Wellcome Trust Case Control Consortium 2 [https://www.wtccc.org.uk/;WTCCC2:EGAD00000000022,%20EGAD00000000024]. Case and control genotyping data from 1615 individuals recruited to the KORA study can be obtained via application at https://www.helmholtz-muenchen.de/en/kora/. Other genotyping data supporting the findings of this study can be found as deposited in NCBI Gene Expression Omnibus under accession numbers GSE20672, GSE32462, GSE34542, GSE46745, and GSE46951. eQTL data is available from the eQTLGen consortium via http://www.eqtlgen.org/cis-eqtls.html. ENCODE data is available from https://www.encodeproject.org/biosamples/ENCBS718AAA/ for H1 human embryonic stem cells (H1hesc) and from https://www.encodeproject.org/biosamples/ENCBS109ENC/ for K562 myeloid leukemia cells. URLs: Michigan Imputation Server, https://imputationserver.sph.umich.edu/index.html#!; Haplotype Reference Consortium, http://www.haplotype-reference-consortium.org/; eQTLGen Consortium, http://www.eqtlgen.org/cis-eqtls.html; 1000 Genomes Project, https://www.internationalgenome.org/; PLINK, https://www.cog-genomics.org/plink2/; SNPTEST2, https://www.well.ox.ac.uk/~gav/snptest/; Phenoscanner, http://www.phenoscanner.medschl.cam.ac.uk/;76 UK Biobank, https://www.ukbiobank.ac.uk/; Central England Haemato-Oncology and Oncology Research Bank, https://bwc.nhs.uk/central-england-haemato-oncology-and-oncology-research-bioba/; Newcastle University Biobank, https://www.ncl.ac.uk/biobanks/; WTCCC, https://www.wtccc.org.uk/; ENCODE, https://www.encodeproject.org/; Study Alliance Leukemia, https://www.sal-aml.org/ueber-uns/einfuehrung-ueberblick.

Competing interests

The authors declare no competing interests.

Footnotes

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

1/4/2022

A Correction to this paper has been published: 10.1038/s41467-021-27679-6

Contributor Information

Friedrich Stölzel, Email: friedrich.stoelzel@uniklinikum-dresden.de.

Kenan Onel, Email: kenan.onel@mssm.edu.

James M. Allan, Email: james.allan@newcastle.ac.uk

Supplementary information

The online version contains supplementary material available at 10.1038/s41467-021-26551-x.

References

  • 1.Smith, A. et al. Cohort profile: The Haematological Malignancy Research Network (HMRN); a UK population-based patient cohort. Int. J. Epidemiol. 47, 700–700g (2018). [DOI] [PMC free article] [PubMed]
  • 2.Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 2016;374:2209–2221. doi: 10.1056/NEJMoa1516192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017;130:424–432. doi: 10.1182/blood-2017-02-735290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wartiovaara-Kautto U, et al. Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia. 2018;32:2282–2285. doi: 10.1038/s41375-018-0049-5. [DOI] [PubMed] [Google Scholar]
  • 5.Sud A, et al. Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Blood. 2018;132:973–976. doi: 10.1182/blood-2018-06-858597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat. Rev. Cancer. 2010;10:353–361. doi: 10.1038/nrc2840. [DOI] [PubMed] [Google Scholar]
  • 7.Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 2018;50:1219–1224. doi: 10.1038/s41588-018-0183-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.McCarthy S, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 2016;48:1279–1283. doi: 10.1038/ng.3643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wakefield J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am. J. Hum. Genet. 2007;81:208–227. doi: 10.1086/519024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Walker, C. J. et al. Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia33, 771–775 (2018). [DOI] [PMC free article] [PubMed]
  • 11.Võsa U, et al. Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis. bioRxiv. 2018 doi: 10.1101/447367,. [DOI] [Google Scholar]
  • 12.Jia X, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE. 2013;8:e64683. doi: 10.1371/journal.pone.0064683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Brohm A, et al. Somatic cancer mutations in the SUV420H1 protein lysine methyltransferase modulate its catalytic activity. J. Mol. Biol. 2019;431:3068–3080. doi: 10.1016/j.jmb.2019.06.021. [DOI] [PubMed] [Google Scholar]
  • 14.Plass C, et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 2013;14:765–780. doi: 10.1038/nrg3554. [DOI] [PubMed] [Google Scholar]
  • 15.Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016;17:284–299. doi: 10.1038/nrg.2016.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mian SA, et al. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat. Commun. 2015;6:10004. doi: 10.1038/ncomms10004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Meyer C, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–284. doi: 10.1038/leu.2017.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cimmino L, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079–1095 e1020. doi: 10.1016/j.cell.2017.07.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009;360:2289–2301. doi: 10.1056/NEJMoa0810069. [DOI] [PubMed] [Google Scholar]
  • 20.Yao CY, et al. A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes. Blood Adv. 2017;1:1505–1516. doi: 10.1182/bloodadvances.2017008284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Khalaj, M. et al. miR-99 regulates normal and malignant hematopoietic stem cell self-renewal. J. Exp. Med. 214, 2453–2470 (2017). [DOI] [PMC free article] [PubMed]
  • 22.Si X, et al. Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. Oncotarget. 2016;7:78095–78109. doi: 10.18632/oncotarget.12947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hu CJ, et al. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol. Cell Biol. 2006;26:3514–3526. doi: 10.1128/MCB.26.9.3514-3526.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vukovic M, et al. Hif-1alpha and Hif-2alpha synergize to suppress AML development but are dispensable for disease maintenance. J. Exp. Med. 2015;212:2223–2234. doi: 10.1084/jem.20150452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Velasco-Hernandez T, Hyrenius-Wittsten A, Rehn M, Bryder D, Cammenga J. HIF-1alpha can act as a tumor suppressor gene in murine acute myeloid leukemia. Blood. 2014;124:3597–3607. doi: 10.1182/blood-2014-04-567065. [DOI] [PubMed] [Google Scholar]
  • 26.Di Bernardo MC, et al. Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation. Leukemia. 2013;27:255–258. doi: 10.1038/leu.2012.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Slager SL, et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood. 2012;120:843–846. doi: 10.1182/blood-2012-03-413591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sud A, et al. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat. Commun. 2017;8:1892. doi: 10.1038/s41467-017-00320-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.McGranahan N, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–1271 e1211. doi: 10.1016/j.cell.2017.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin. Cancer Res. 2014;20:6034–6044. doi: 10.1158/1078-0432.CCR-14-0879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Marty R, et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell. 2017;171:1272–1283 e1215. doi: 10.1016/j.cell.2017.09.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Stolzel F, et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation. 2012;93:744–749. doi: 10.1097/TP.0b013e3182481113. [DOI] [PubMed] [Google Scholar]
  • 33.Crucitti L, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29:1143–1152. doi: 10.1038/leu.2014.314. [DOI] [PubMed] [Google Scholar]
  • 34.Vago L, Toffalori C, Ciceri F, Fleischhauer K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin. Oncol. 2012;39:707–715. doi: 10.1053/j.seminoncol.2012.09.009. [DOI] [PubMed] [Google Scholar]
  • 35.McCurdy SR, et al. Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia. 2016;30:2102–2106. doi: 10.1038/leu.2016.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.van der Lee DI, et al. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. J. Clin. Investig. 2019;129:774–785. doi: 10.1172/JCI97482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Roerden M, Nelde A, Walz JS. Neoantigens in hematological malignancies-ultimate targets for immunotherapy? Front. Immunol. 2019;10:3004. doi: 10.3389/fimmu.2019.03004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Narayan R, et al. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. PLoS ONE. 2019;14:e0219547. doi: 10.1371/journal.pone.0219547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Greiner J, et al. Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition. Haematologica. 2017;102:e499–e501. doi: 10.3324/haematol.2017.176461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Greiner J, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood. 2012;120:1282–1289. doi: 10.1182/blood-2011-11-394395. [DOI] [PubMed] [Google Scholar]
  • 41.Dohner K, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740–3746. doi: 10.1182/blood-2005-05-2164. [DOI] [PubMed] [Google Scholar]
  • 42.Becker H, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2010;28:596–604. doi: 10.1200/JCO.2009.25.1496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Liso A, et al. Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. Leukemia. 2008;22:424–426. doi: 10.1038/sj.leu.2404887. [DOI] [PubMed] [Google Scholar]
  • 44.Alshiekh S, et al. Different DRB1*03:01-DQB1*02:01 haplotypes confer different risk for celiac disease. HLA. 2017;90:95–101. doi: 10.1111/tan.13065. [DOI] [PubMed] [Google Scholar]
  • 45.Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat. Rev. Endocrinol. 2017;13:674–686. doi: 10.1038/nrendo.2017.99. [DOI] [PubMed] [Google Scholar]
  • 46.Karnes, J. H. et al. Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci. Transl. Med. 9, eaai8708 (2017). [DOI] [PMC free article] [PubMed]
  • 47.Anderson LA, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br. J. Cancer. 2009;100:822–828. doi: 10.1038/sj.bjc.6604935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Schwab A, et al. Polyol pathway links glucose metabolism to the aggressiveness of cancer cells. Cancer Res. 2018;78:1604–1618. doi: 10.1158/0008-5472.CAN-17-2834. [DOI] [PubMed] [Google Scholar]
  • 49.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
  • 50.Chen WL, et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014;124:1645–1654. doi: 10.1182/blood-2014-02-554204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Chen WL, et al. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell. 2016;30:779–791. doi: 10.1016/j.ccell.2016.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Jeong S, et al. High fructose drives the serine synthesis pathway in acute myeloid leukemic cells. Cell Metab. 2021;33:145–159 e146. doi: 10.1016/j.cmet.2020.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Laffin B, Petrash JM. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in human cancers. Front. Pharmacol. 2012;3:104. doi: 10.3389/fphar.2012.00104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Burnett AK, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J. Clin. Oncol. 2010;28:586–595. doi: 10.1200/JCO.2009.22.9088. [DOI] [PubMed] [Google Scholar]
  • 55.Goldstone AH, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302–1311. doi: 10.1182/blood.v98.5.1302. [DOI] [PubMed] [Google Scholar]
  • 56.Dickinson AM, et al. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br. J. Haematol. 2004;127:479–490. doi: 10.1111/j.1365-2141.2004.05216.x. [DOI] [PubMed] [Google Scholar]
  • 57.Kane EV, Roman E, Cartwright R, Parker J, Morgan G. Tobacco and the risk of acute leukaemia in adults. Br. J. Cancer. 1999;81:1228–1233. doi: 10.1038/sj.bjc.6690833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Allan JM, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. USA. 2001;98:11592–11597. doi: 10.1073/pnas.191211198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Power C, Elliott J. Cohort profile: 1958 British birth cohort (National Child Development Study) Int. J. Epidemiol. 2006;35:34–41. doi: 10.1093/ije/dyi183. [DOI] [PubMed] [Google Scholar]
  • 60.Rollig C, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J. Clin. Oncol. 2015;33:403–410. doi: 10.1200/JCO.2013.54.4973. [DOI] [PubMed] [Google Scholar]
  • 61.Schaich M, et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J. Clin. Oncol. 2013;31:2094–2102. doi: 10.1200/JCO.2012.46.4743. [DOI] [PubMed] [Google Scholar]
  • 62.Powell BL, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751–3757. doi: 10.1182/blood-2010-02-269621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447, 661–678 (2007). [DOI] [PMC free article] [PubMed]
  • 64.Nowak D, et al. SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes. Chromosomes Cancer. 2012;51:756–767. doi: 10.1002/gcc.21961. [DOI] [PubMed] [Google Scholar]
  • 65.Cluzeau T, et al. Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J. 2013;3:e155. doi: 10.1038/bcj.2013.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Milosevic JD, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am. J. Hematol. 2012;87:1010–1016. doi: 10.1002/ajh.23309. [DOI] [PubMed] [Google Scholar]
  • 67.Renneville A, et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget. 2014;5:916–932. doi: 10.18632/oncotarget.1536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Nibourel O, et al. Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia. 2017;31:555–564. doi: 10.1038/leu.2016.265. [DOI] [PubMed] [Google Scholar]
  • 69.Gomez-Segui I, et al. Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia. PLoS ONE. 2014;9:e100245. doi: 10.1371/journal.pone.0100245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Kuhn MW, et al. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood. 2012;119:e67–e75. doi: 10.1182/blood-2011-09-380444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Rucker FG, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119:2114–2121. doi: 10.1182/blood-2011-08-375758. [DOI] [PubMed] [Google Scholar]
  • 72.Kronke J, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100–108. doi: 10.1182/blood-2013-01-479188. [DOI] [PubMed] [Google Scholar]
  • 73.Wichmann HE, Gieger C, Illig T, Group MKS. KORA-gen–resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen. 2005;67:S26–S30. doi: 10.1055/s-2005-858226. [DOI] [PubMed] [Google Scholar]
  • 74.Gagyi E, et al. Prognostic significance and detection of the internal tandem duplication of the FLT3 gene in acute myeloid leukemia. Rom. J. Morphol. Embryol. 2006;47:331–337. [PubMed] [Google Scholar]
  • 75.Rollinson S, et al. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia. Carcinogenesis. 2000;21:43–47. doi: 10.1093/carcin/21.1.43. [DOI] [PubMed] [Google Scholar]
  • 76.Zebisch A, et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 2006;66:3401–3408. doi: 10.1158/0008-5472.CAN-05-0115. [DOI] [PubMed] [Google Scholar]
  • 77.Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat. Methods. 2011;9:179–181. doi: 10.1038/nmeth.1785. [DOI] [PubMed] [Google Scholar]
  • 78.Schlenk RF, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008;358:1909–1918. doi: 10.1056/NEJMoa074306. [DOI] [PubMed] [Google Scholar]
  • 79.Kiyoi H, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–3080. [PubMed] [Google Scholar]
  • 80.Grimwade D, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365. doi: 10.1182/blood-2009-11-254441. [DOI] [PubMed] [Google Scholar]
  • 81.de Souza N. The ENCODE project. Nat. Methods. 2012;9:1046. doi: 10.1038/nmeth.2238. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information (8.4MB, pdf)
Peer Review File (1MB, pdf)
Reporting summary (220.2KB, pdf)

Data Availability Statement

Genome-wide association summary statistics (Lin_AML_metaassoc.txt) are available for download from 10.25405/data.ncl.16558116.v1. AML case and control genotyping data from the UK Biobank can be obtained via application through https://www.ukbiobank.ac.uk/. Genotyping data on 2699 individuals recruited to the 1958 British Birth Cohort (Hap1.2M-Duo Custom array data) and 2501 individuals from the UK Blood Service are available from the Wellcome Trust Case Control Consortium 2 [https://www.wtccc.org.uk/;WTCCC2:EGAD00000000022,%20EGAD00000000024]. Case and control genotyping data from 1615 individuals recruited to the KORA study can be obtained via application at https://www.helmholtz-muenchen.de/en/kora/. Other genotyping data supporting the findings of this study can be found as deposited in NCBI Gene Expression Omnibus under accession numbers GSE20672, GSE32462, GSE34542, GSE46745, and GSE46951. eQTL data is available from the eQTLGen consortium via http://www.eqtlgen.org/cis-eqtls.html. ENCODE data is available from https://www.encodeproject.org/biosamples/ENCBS718AAA/ for H1 human embryonic stem cells (H1hesc) and from https://www.encodeproject.org/biosamples/ENCBS109ENC/ for K562 myeloid leukemia cells. URLs: Michigan Imputation Server, https://imputationserver.sph.umich.edu/index.html#!; Haplotype Reference Consortium, http://www.haplotype-reference-consortium.org/; eQTLGen Consortium, http://www.eqtlgen.org/cis-eqtls.html; 1000 Genomes Project, https://www.internationalgenome.org/; PLINK, https://www.cog-genomics.org/plink2/; SNPTEST2, https://www.well.ox.ac.uk/~gav/snptest/; Phenoscanner, http://www.phenoscanner.medschl.cam.ac.uk/;76 UK Biobank, https://www.ukbiobank.ac.uk/; Central England Haemato-Oncology and Oncology Research Bank, https://bwc.nhs.uk/central-england-haemato-oncology-and-oncology-research-bioba/; Newcastle University Biobank, https://www.ncl.ac.uk/biobanks/; WTCCC, https://www.wtccc.org.uk/; ENCODE, https://www.encodeproject.org/; Study Alliance Leukemia, https://www.sal-aml.org/ueber-uns/einfuehrung-ueberblick.

Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES